Sanofi
Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results
Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
Eisai poaches senior Pfizer and Sanofi execs for neurology group
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eisai, Pfizer, Sanofi, appointments, hawthorne, zaim
Eisai has made new appointments to its US neurology business group, bringing in senior executives who have previously held positions …
A win for Sanofi on Jevtana after NICE reverses guidance
April 22, 2016Medical Communications, Sales and Marketing Cancer Drugs Fund, Jevtana, NICE, Sanofi, recommendation, reversal
Prostate cancer treatment Jevtana (cabazitaxel), marketed by Sanofi (NYSE: SNY) has been recommended by NICE in its final guidance. The …
Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
April 20, 2016Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Sanofi invests €300 million in new Belgian biologics site
April 19, 2016Manufacturing and Production Belgium, Sanofi, belgian, flanders, geel, investment, manufacturing, pipeline
Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
Research shows Novartis’s Entresto reduces cardiovascular death and heart failure
April 4, 2016Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent
Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
Amgen’s high cholesterol drug at centre of patent court case yields positive clinical trial results
April 4, 2016Research and Development, Sales and Marketing Amgen, Repatha, Sanofi, high cholesterol. ldl, ldl-c, phase III, statins
Amgen has announced positive results from the Phase III GAUSS-3 clinical trial evaluating Repatha (evolucumab) in patients with high cholesterol …
Sanofi’s dengue vaccine rolled out for world’s first public immunisation program
April 4, 2016Sales and Marketing Philippines, Sanofi, Vaccine, children, dengue, dengvaxia, immunisation, prevention, public health
Sanofi, along with its vaccines global business unit Sanofi Pasteur, has announced the beginning of the first public dengue immunisation …
Sanofi and Regeneron announce positive Phase III trial results for chronic skin disease treatment
April 1, 2016Medical Communications, Research and Development Dupilumab, Regeneron, Sanofi, atopic dermatitis, phase III, skin disease
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have announced positive top line results for dupilumab in Phase III clinical …
Sanofi and Regeneron meet endpoint in Phase III Praluent study
March 23, 2016Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Amgen wins high-profile cholesterol drug patent case v Sanofi
March 17, 2016Sales and Marketing Amgen, PCSK9, Regeneron, Repatha, Sanofi, cholesterol, praluent
A Delaware district court jury has ruled in favour of Amgen in an ongoing dispute around patents for cholesterol-lowering drugs …
Sanofi to use DiCE Molecules’ platform to boost drug discovery
March 16, 2016Research and Development DiCE Molecules, Sanofi
Sanofi has announced a research partnership with newly-launched DiCE Molecules in which the French pharma giant will use DiCE’s small …
Latest content
Five Facts about cardiovascular disease
